Latest news with #AnaptysBio
Business Insider
31-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), AnaptysBio (ANAB) and Alignment Healthcare (ALHC)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Guardant Health (GH – Research Report), AnaptysBio (ANAB – Research Report) and Alignment Healthcare (ALHC – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Guardant Health (GH) In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health, with a price target of $60.00. The company's shares closed last Monday at $44.05. According to Westenberg is a 3-star analyst with an average return of 3.1% and a 44.4% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Elanco Animal Health, and Pacific Biosciences. Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $59.26, which is a 29.4% upside from current levels. In a report issued on April 22, Leerink Partners also maintained a Buy rating on the stock. AnaptysBio (ANAB) In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on AnaptysBio, with a price target of $57.00. The company's shares closed last Monday at $20.73. According to Rahimi is a 1-star analyst with an average return of -1.0% and a 34.8% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, NewAmsterdam Pharma Company, and Praxis Precision Medicines. The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio with a $45.57 average price target, which is a 120.2% upside from current levels. In a report issued on April 22, Wells Fargo also maintained a Buy rating on the stock with a $51.00 price target. Alignment Healthcare (ALHC) In a report released today, Jessica Tassan from Piper Sandler maintained a Buy rating on Alignment Healthcare, with a price target of $21.00. The company's shares closed last Monday at $15.48. According to Tassan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.8% and a 39.2% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Privia Health Group, Health Catalyst, and Evolent Health. Currently, the analyst consensus on Alignment Healthcare is a Moderate Buy with an average price target of $18.35, implying a 18.6% upside from current levels. In a report issued on May 2, TD Cowen also maintained a Buy rating on the stock with a $17.00 price target.
Yahoo
12-05-2025
- Business
- Yahoo
AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now
We recently published a list of . In this article, we are going to take a look at where AnaptysBio, Inc. (NASDAQ:ANAB) stands against other unstoppable growth stocks to invest in now. BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions. However, the expectations of a supply-driven contraction in the US are very different from a typical business cycle recession. The hard economic rules binding on policy are expected to limit the damage. Furthermore, the AI mega force has been keeping the firm overweight on the US stocks and positive on developed market stocks, despite the expectations of volatility. BlackRock believes that some of the sectors are more exposed to tariffs as compared to others, with sectoral differences already at play in the earnings releases for Q1 2025. The companies that are at the forefront of the AI mega force continued to keep fueling the US equity strength, while policy uncertainty significantly impacts the broader market. The leading technology companies managed to exceed the Q1 earnings expectations, highlighted the increasing AI-driven demand, and announced plans to raise investments focused on AI. Such trends strengthen the fact that how AI mega force continues to persist despite the supply-driven disruptions. As a result, BlackRock has remained positive on developed market (DM) stocks, primarily the US. On the other hand, automakers have been tagged by the firm as the ones most exposed to key supply inputs from China. Furthermore, some of the automakers have highlighted the impact of tariffs in their respective expectations for full-year earnings. READ ALSO: and . Franklin Templeton believes that it is of utmost importance to remember that tough economic and/or market phases are finite. Investors who tend to see most of the profits during the recovery are the ones staying the course during the stormy weather. The investment firm continues to see increased potential for a sustained period of small-cap leadership. Considering its metric of choice to gauge index valuations, EV/EBIT, the Russell 2000 is far more attractively valued as compared to the Russell 1000, says Franklin Templeton. As per the investment manager, the valuation situation becomes even more attractive when consensus earnings growth is included. Notably, growth stocks are the ones capable of increasing their earnings faster as compared to an average business in the respective industry or broader market. At 2024 end, the Russell 2000 was expected to see stronger earnings growth in 2025 as compared to the Russell 1000, based on EPS, added the investment firm. To list the 11 Unstoppable Growth Stocks to Invest in Now, we used a screener to shortlist the companies catering to the growth sectors that have 3-year revenue growth of at least ~25%, and that have appreciated significantly on a YTD basis. We also mentioned hedge fund sentiments around each stock, as of Q4 2024. Finally, the stocks were arranged in ascending order of their hedge fund sentiment. Note: The data was recorded on May 9. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A scientist in a biotechnology laboratory studying a new therapeutic product Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company, focusing on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. Leerink Partners analyst David Risinger has maintained a bullish stance on the company's stock, giving it a Buy rating. The analyst's rating is backed by factors associated with its strategic collaborations and potential financial gains. The strong increase in sales of Jemperli, a product under AnaptysBio, Inc. (NASDAQ:ANAB)'s collaboration with GSK, demonstrates healthy market performance and future growth potential. GSK announced robust commercial performance for Jemperli ($220 million in Q1 2025 sales) with more than 15% Q-o-Q growth. Furthermore, there are expectations of receipt of a $75 million commercial sales milestone payment from GSK in either 2025 or 2026 after Jemperli achieves $1 billion in worldwide net sales in a calendar year. The expansion of Jemperli's market presence, which includes recent approvals in multiple countries, further aids the analyst's positive outlook. In Q1 2025, the collaboration revenue came in at $27.8 million as compared to $7.2 million in Q1 2024. This rise was off the back of a $11.0 million increase in royalties recognized for sales of Jemperli and $9.6 million in revenue recognized for the Vanda license agreement. Overall, ANAB ranks 10th on our list of unstoppable growth stocks to invest in now. While we acknowledge the potential of ANAB as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for a deeply undervalued AI stock that is more promising than ANAB but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
12-05-2025
- Business
- Yahoo
AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now
We recently published a list of . In this article, we are going to take a look at where AnaptysBio, Inc. (NASDAQ:ANAB) stands against other unstoppable growth stocks to invest in now. BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions. However, the expectations of a supply-driven contraction in the US are very different from a typical business cycle recession. The hard economic rules binding on policy are expected to limit the damage. Furthermore, the AI mega force has been keeping the firm overweight on the US stocks and positive on developed market stocks, despite the expectations of volatility. BlackRock believes that some of the sectors are more exposed to tariffs as compared to others, with sectoral differences already at play in the earnings releases for Q1 2025. The companies that are at the forefront of the AI mega force continued to keep fueling the US equity strength, while policy uncertainty significantly impacts the broader market. The leading technology companies managed to exceed the Q1 earnings expectations, highlighted the increasing AI-driven demand, and announced plans to raise investments focused on AI. Such trends strengthen the fact that how AI mega force continues to persist despite the supply-driven disruptions. As a result, BlackRock has remained positive on developed market (DM) stocks, primarily the US. On the other hand, automakers have been tagged by the firm as the ones most exposed to key supply inputs from China. Furthermore, some of the automakers have highlighted the impact of tariffs in their respective expectations for full-year earnings. READ ALSO: and . Franklin Templeton believes that it is of utmost importance to remember that tough economic and/or market phases are finite. Investors who tend to see most of the profits during the recovery are the ones staying the course during the stormy weather. The investment firm continues to see increased potential for a sustained period of small-cap leadership. Considering its metric of choice to gauge index valuations, EV/EBIT, the Russell 2000 is far more attractively valued as compared to the Russell 1000, says Franklin Templeton. As per the investment manager, the valuation situation becomes even more attractive when consensus earnings growth is included. Notably, growth stocks are the ones capable of increasing their earnings faster as compared to an average business in the respective industry or broader market. At 2024 end, the Russell 2000 was expected to see stronger earnings growth in 2025 as compared to the Russell 1000, based on EPS, added the investment firm. To list the 11 Unstoppable Growth Stocks to Invest in Now, we used a screener to shortlist the companies catering to the growth sectors that have 3-year revenue growth of at least ~25%, and that have appreciated significantly on a YTD basis. We also mentioned hedge fund sentiments around each stock, as of Q4 2024. Finally, the stocks were arranged in ascending order of their hedge fund sentiment. Note: The data was recorded on May 9. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A scientist in a biotechnology laboratory studying a new therapeutic product Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company, focusing on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. Leerink Partners analyst David Risinger has maintained a bullish stance on the company's stock, giving it a Buy rating. The analyst's rating is backed by factors associated with its strategic collaborations and potential financial gains. The strong increase in sales of Jemperli, a product under AnaptysBio, Inc. (NASDAQ:ANAB)'s collaboration with GSK, demonstrates healthy market performance and future growth potential. GSK announced robust commercial performance for Jemperli ($220 million in Q1 2025 sales) with more than 15% Q-o-Q growth. Furthermore, there are expectations of receipt of a $75 million commercial sales milestone payment from GSK in either 2025 or 2026 after Jemperli achieves $1 billion in worldwide net sales in a calendar year. The expansion of Jemperli's market presence, which includes recent approvals in multiple countries, further aids the analyst's positive outlook. In Q1 2025, the collaboration revenue came in at $27.8 million as compared to $7.2 million in Q1 2024. This rise was off the back of a $11.0 million increase in royalties recognized for sales of Jemperli and $9.6 million in revenue recognized for the Vanda license agreement. Overall, ANAB ranks 10th on our list of unstoppable growth stocks to invest in now. While we acknowledge the potential of ANAB as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for a deeply undervalued AI stock that is more promising than ANAB but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
08-05-2025
- Business
- Forbes
We Need Progress, Not Just The Progress Congress Will ‘Pay For'
CHICAGO - JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. ... More Pfizer, the world's biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today its second quarter profit rose to $2.78 billion. Lipitor is the world's top-selling drug. (Photo by) Congress is considering reducing the amount of time that pharmaceutical drugs will be patent protected. Stop and think about that. Congress is presently fiddling with the tax code to 'pay for' the tax priorities of certain members. This is taking place as members of Congress work to extend the 2017 Tax Cuts and Jobs Act. Supposedly the path to getting it extended includes 'paying for it' with the reduction of patent protection for pharmaceutical drugs. Something's very wrong with this picture. To see why, it's useful to contemplate Revolution Medicine's daraxonrasib. The drug is making it possible for patients to survive one of the most consistent modern killers of all, pancreatic cancer. Away from daraxonrasib, AnaptysBio and GlaxoSmithKline's dostarlimab is making it possible for doctors to treat cancer without chemotherapy, radiation and the cutting out of infected organs. What's important about this broadly is that the innovators developing crucial drugs for patients very much desire patent protection. So, while wise minds can and will continue to debate the value of patent protection, let's forget debates for now and just think about possible changes in the tax code with drugmakers well in mind. Major pharmaceutical companies want the patent protection given the immense costs associated with developing lifesaving and life-enhancing drugs. Which means a reduction in the number of years of patent protection to 'pay for' other tax priorities reads as offensive and wrongheaded no matter one's position on patent protection. Progress on the health front might be halted a little or a lot because members of Congress have other tax cuts they want to 'pay for'? The question must be asked simply because pharmaceutical companies view a reduction in the length of time patents are protected as a substantial cost, one that would make much more costly the development of drugs that have high odds of failure, but that by virtue of the latter have high odds of elongating or saving lives if they succeed. Which is a reminder that the tax cuts some in Congress want to pay for will be paid for by others. All of which calls for a rethink of how Congress views the writing of tax law. It needs to be clarified that tax cuts are never a cost. Such a view implies that Congress exists as the benevolent source of good, and that the good it presumes to dole out is paid for by it. No, not remotely. Congress is an effect of us. Congress has funds and taxing power not because it's Congress, but because it has taxing power over the American people it serves. By extension, anytime Congress reduces the tax burden on individuals and businesses, there is no cost associated with it. How could there be? To suggest there is, and as Congress is presently doing, is for members elected to serve us to presume that we're working for them. No thanks. We're the ones in charge. Since we are, the notion that Congress will potentially sacrifice pharmaceutical progress on the altar of 'paid for' tax cuts brings new meaning to insult. Americans are taxed too much, and they also suffer or die too easily because drugs that could dim their suffering and elongate their lives don't yet exist. Let's not sacrifice a much better, much healthier future on the false notion that we work for Congress, and that a reduction of the burden of Congress is something we the people must 'pay for.'
